NEW YORK — Todos Medical said on Tuesday that it has acquired US rights to sell Osang Healthcare's GeneFinder COVID-19 Plus RealAmp Kit.
The PCR-based test kit, which received Emergency Use Authorization from the US Food and Drug Administration about a year ago, is designed to detect SARS-CoV-2 nucleic acid in nasal swab specimens and other samples. Rehovat, Israel-based Todos said it will work with Osang to expand authorized use of the test to include saliva samples.
Todos said that the agreement with Osang allows it to sell, market, and distribute the test in the US. Financial and other terms of the deal were not disclosed.
"As a result of our newly established supply chain in the United States, we will be able to deliver GeneFinder Plus kits anywhere in the US within 48 [hours] of ordering," Osang Chairman and CEO Dong-Hyun Lee said in a statement.
SG Blocks, which designs and builds structures using maritime-grade shipping containers, also holds US distribution rights to the GeneFinder COVID-19 test under a May 2020 agreement. In December, South Korea-based Osang inked a manufacturing and supply deal for the test with Nexus Dx.